EMVision Medical Devices’ recent trial data has shown promising results in identifying different types of strokes, according to a report by a leading global news publisher.
The Stage 2 interim data from a pre-validation trial conducted by EMVision Medical Devices has confirmed the positive performance of neurodiagnostic artificial intelligence (AI) algorithms in diagnosing suspected haemorrhagic or ischaemic strokes.
The trial involved 180 patients who had presented with stroke-like symptoms at various hospitals, with 75 patients having confirmed ischaemic strokes. The data showcased the algorithms’ ability to identify patterns and features in complex ischaemic patient data sets, including early onset hyperacute ischaemic strokes.
Patients were evaluated using the Alberta Stroke Program Early CT Score (ASPECTS), with the average ASPECTS score for the ischaemic stroke cohort being 7.4 in Stage 2 of the trial.
EMVision’s AI model demonstrated the potential to significantly improve the diagnosis, care, and outcomes for haemorrhagic and ischaemic stroke patients, particularly by detecting hyperacute and acute ischaemic cases effectively.
The company is now utilizing this data to enhance its AI algorithms, with a focus on validation trials to confirm sensitivity and specificity. The aim is to improve the detection and classification performance of the AI algorithm, particularly in distinguishing between ischaemic and non-ischaemic cases.
EMVision’s CEO, Scott Kirkland, expressed his excitement about the interim data, emphasizing the technology’s ability to enhance care pathways and outcomes for stroke patients. Patient recruitment for the final Stage 3 of the pre-validation clinical trial is progressing well, with over half of the target cohort already recruited.
As the clinical trial advances, the company looks forward to expanding its neurodiagnostic capabilities and providing accessible and easy-to-use technology for indicating likely haemorrhagic or ischaemic strokes.
Overall, the interim trial data from EMVision Medical Devices shows promising potential in revolutionizing stroke diagnosis and treatment, offering hope for improved patient outcomes in the future.
